Miromatrix Medical Stock Soars 236% After It Agrees to Be Bought By United Therapeutics

4
Comment
Favorite

Miromatrix Medical Stock Soars 236% After It Agrees to Be Bought By United Therapeutics

Dow Jones2023-10-30

Miromatrix Medical Inc.’s stock jumped 235.6% in premarket trades on Monday after the company agreed to be acquired by United Therapeutics Corp. for $3.25 per share in cash, or about $91 million.

The deal also includes a milestone payment of $1.75 per share in cash upon the achievement of clinical development of Miromatrix’s development-stage, fully-implantable manufactured kidney product, Mirokidney by Dec. 31, 2025.

The price of $3.25 a share amounts to a premium of approximately 170% to the 30-day volume-weighted average trading price of Miromatrix’s common stock as of Friday.

Miromatrix’s board has recommended that Miromatrix’s stockholders agree to the offer. The deal is expected to close in the fourth quarter.

United Therapeutics’s stock is down 21% so far in 2023, compared to a 20.8% rise by the Nasdaq.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2379306016?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-10-30 18:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2379306016","market":"us","top_or_hot":-1,"title":"Miromatrix Medical Stock Soars 236% After It Agrees to Be Bought By United Therapeutics","media":"Dow Jones","content":"<html><head></head><body><p>Miromatrix Medical Inc.’s stock jumped 235.6% in premarket trades on Monday after the company agreed to be acquired by United Therapeutics Corp. for $3.25 per share in cash, or about $91 million. </p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f47aa5189be75a2ba3297430d5ed1991\" title=\"\" tg-width=\"842\" tg-height=\"621\"/></p><p>The deal also includes a milestone payment of $1.75 per share in cash upon the achievement of clinical development of Miromatrix’s development-stage, fully-implantable manufactured kidney product, Mirokidney by Dec. 31, 2025. </p><p>The price of $3.25 a share amounts to a premium of approximately 170% to the 30-day volume-weighted average trading price of Miromatrix’s common stock as of Friday. </p><p>Miromatrix’s board has recommended that Miromatrix’s stockholders agree to the offer. The deal is expected to close in the fourth quarter. </p><p>United Therapeutics’s stock is down 21% so far in 2023, compared to a 20.8% rise by the Nasdaq.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Miromatrix Medical Stock Soars 236% After It Agrees to Be Bought By United Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMiromatrix Medical Stock Soars 236% After It Agrees to Be Bought By United Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-10-30 18:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Miromatrix Medical Inc.’s stock jumped 235.6% in premarket trades on Monday after the company agreed to be acquired by United Therapeutics Corp. for $3.25 per share in cash, or about $91 million. The ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2379306016","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2379306016","pubTimestamp":1698661986,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Miromatrix Medical Inc.’s stock jumped 235.6% in premarket trades on Monday after the company agreed to be acquired by United Therapeutics Corp. for $3.25 per share in cash, or about $91 million. The deal also includes a milestone payment of $1.75 per share in cash upon the achievement of clinical development of Miromatrix’s development-stage, fully-implantable manufactured kidney product, Mirokidney by Dec. 31, 2025. The price of $3.25 a share amounts to a premium of approximately 170% to the 3","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","BK4532":"文艺复兴科技持仓","UTHR":"美国联合医疗","BK4121":"生命科学工具和服务","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC"},"translate_title":"Miromatrix Medical股票在同意被联合治疗公司收购后飙升236%","themeId":"c5bbfdf5f7964880af97c1d6f417052c","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":1},"content_text":"Miromatrix Medical Inc.’s stock jumped 235.6% in premarket trades on Monday after the company agreed to be acquired by United Therapeutics Corp. for $3.25 per share in cash, or about $91 million. The deal also includes a milestone payment of $1.75 per share in cash upon the achievement of clinical development of Miromatrix’s development-stage, fully-implantable manufactured kidney product, Mirokidney by Dec. 31, 2025. The price of $3.25 a share amounts to a premium of approximately 170% to the 30-day volume-weighted average trading price of Miromatrix’s common stock as of Friday. Miromatrix’s board has recommended that Miromatrix’s stockholders agree to the offer. The deal is expected to close in the fourth quarter. United Therapeutics’s stock is down 21% so far in 2023, compared to a 20.8% rise by the Nasdaq.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}